NightHawk Biosciences Appoints Stephan Kutzer, Ph.D. as Interim Chief Executive Officer of Scorpion Biological Services
13 Juin 2022 - 2:00PM
NightHawk Biosciences (NYSE American:
NHWK), a fully integrated biopharmaceutical company
focused on developing first-in-class therapies to modulate the
immune system, today announced the appointment of Stephan Kutzer,
Ph.D. as Interim Chief Executive Officer of Scorpion Biological
Services. Dr. Kutzer currently serves on Scorpion’s advisory board.
Dr. Kutzer brings more than 25 years of
experience in the pharmaceutical and biotech industries, building
and managing successful contract development and manufacturing
organizations. He previously served as President and Chief
Executive Officer of Alcami Corporation, a leading provider of
development, analytical testing and manufacturing services to the
pharmaceutical and biotech industries. Prior to this, he served as
President, Divisional CEO and Chief Operating Officer of the Pharma
Biotech & Customer Manufacturing division of Lonza Group AG, a
multinational manufacturing company for the pharmaceutical and
biotechnology sectors, where he had full oversight of the division,
which generated over $1.6 billion in annual sales. He also served
as a member of the Executive Management Board of Lonza Group AG;
President of Lonza Biologics Inc; Chairman of the Board of
Directors of Lonza Singapore Inc; Chairman of the Board of
Directors of Teva-Lonza TL Biopharmaceuticals AG; Chairman of the
Board of Directors of Lonza Biologics plc.; and President and
Chairman of Lonza Inc. Dr. Kutzer previously served as an Executive
Director on the board of directors for the Drug, Chemical &
Associated Technologies Association (DCAT). Dr. Kutzer earned a
master’s degree in Chemical and Process Engineering and a Ph.D. in
Engineering Sciences from the Technical University of Munich,
Germany.
Jeff Wolf, CEO of NightHawk and Chairman of
Scorpion, commented, “Given the dynamic evolution of Scorpion and
rapid progress with construction of our San Antonio and Manhattan,
Kansas biomanufacturing facilities, we are delighted to welcome
Stephan on board. Throughout his more than 25 years in the
biomanufacturing space, Stephan has built and managed several
successful contract development and global manufacturing
organizations. We tapped Stephan from Scorpion’s advisory board to
lead Scorpion through its next phase of growth, and we believe his
proven track record will be invaluable to our future success.”
Commenting on his appointment, Dr. Kutzer
stated, “This is an exciting time at Scorpion as we seek to build a
robust and fully integrated CDMO. I am honored to have this
opportunity and look forward to supporting Scorpion through this
next phase of growth.”
About Scorpion Biological
ServicesScorpion Biological Services is a contract
research, and contract development and manufacturing organization
(CDMO) focused on cell- and gene-based therapies and large molecule
biologics. Scorpion provides a broad array of clinical-scale
biomanufacturing, analytical and R&D services to pharmaceutical
and biotech companies from its San Antonio, Texas facilities.
Scorpion also plans to offer commercial-scale biomanufacturing from
its newly announced site in Manhattan, Kansas. Additional
information is available at: https://www.scorpionbio.com/.
NightHawk Biosciences,
Inc.NightHawk Biosciences is a fully integrated
biopharmaceutical company focused on the development of new drugs
from discovery through commercialization. The Company leverages its
integrated ecosystem of subsidiaries to accelerate the development
of novel therapies that arm the immune system, breaking through
barriers that prolong traditional drug development. This empowers
us to bring our ideas to life with efficient control, superior
quality, and uncharacteristic agility.
For more information on the Company and is
subsidiaries, please visit: www.nighthawkbio.com, and also
follow us on Twitter.
Forward Looking StatementThis
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. In some cases
forward-looking statements can be identified by terminology such as
"may," "should," "potential," "continue," "expects," "anticipates,"
"intends," "plans," "believes," "estimates," and similar
expressions, and include statements such as Stephan Kutzer’s proven
track record being invaluable to our future success Important
factors that could cause actual results to differ materially from
current expectations include, among others, the contribution to be
made by Stephan Kutzer, the ability to progress the company’s
efforts under the NightHawk banner, whether the combined business
of NightHawk and Elusys will be successful, NightHawk’s ability to
successfully operate as a CDMO, NightHawk’s and its subsidiaries’
ability to maintain license agreements, the continued maintenance
and growth of NightHawk’s and its subsidiaries’ patent estates,
NightHawk’s product candidates demonstrating safety and
effectiveness, as well as results that are consistent with prior
results, the ability to initiate clinical trials and if initiated,
the ability to complete them on time and achieve the desired
results and benefits continuing enrollment as expected, the ability
to obtain regulatory approval for commercialization of product
candidates or to comply with ongoing regulatory requirements,
regulatory limitations relating to NightHawk’s ability to promote
or commercialize its product candidates for the specific
indications, acceptance of product candidates in the marketplace
and the successful development, marketing or sale of NightHawk’s
products, developments by competitors that render such products
obsolete or non-competitive, and other factors described in
NightHawk’s annual report on Form 10-K for the year ended December
31, 2021, subsequent quarterly reports on Form 10-Qs and any other
filings NightHawk makes with the SEC. The information in this
presentation is provided only as of the date presented, and
NightHawk undertakes no obligation to update any forward-looking
statements contained in this presentation on account of new
information, future events, or otherwise, except as required by
law.
Media and Investor Relations ContactDavid
Waldman+1 919 289 4017investorrelations@heatbio.com
Nighthawk Biosciences (AMEX:NHWK)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Nighthawk Biosciences (AMEX:NHWK)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024